Published in Clin Cancer Res on September 08, 2009
Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood (2010) 3.57
Gene-engineered T cells for cancer therapy. Nat Rev Cancer (2013) 2.07
Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer (2016) 1.51
Immunotherapy of human cancers using gene modified T lymphocytes. Curr Gene Ther (2009) 1.29
Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. Expert Opin Biol Ther (2011) 1.27
Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook. Cancer J (2012) 1.26
A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19. Immunol Rev (2014) 1.14
Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat Med (2015) 1.07
The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting. Br J Cancer (2012) 1.06
OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells. Oncoimmunology (2012) 1.01
Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice. BMC Cancer (2014) 0.95
Cellular immunotherapy for high-grade glioma. Immunotherapy (2011) 0.91
Advances in the treatment of metastatic melanoma: adoptive T-cell therapy. Semin Oncol (2012) 0.90
T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo. Clin Cancer Res (2013) 0.89
Glycobiology of neuroblastoma: impact on tumor behavior, prognosis, and therapeutic strategies. Front Oncol (2014) 0.88
Ganglioside GD2-specific trifunctional surrogate antibody Surek demonstrates therapeutic activity in a mouse melanoma model. J Transl Med (2012) 0.87
Universal artificial antigen presenting cells to selectively propagate T cells expressing chimeric antigen receptor independent of specificity. J Immunother (2014) 0.87
Optimization manufacture of virus- and tumor-specific T cells. Stem Cells Int (2011) 0.86
Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape. J Clin Invest (2016) 0.84
Manufacture of T cells using the Sleeping Beauty system to enforce expression of a CD19-specific chimeric antigen receptor. Cancer Gene Ther (2015) 0.83
Novel anti-melanoma immunotherapies: disarming tumor escape mechanisms. Clin Dev Immunol (2012) 0.82
Focus on adoptive T cell transfer trials in melanoma. Clin Dev Immunol (2010) 0.81
GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade. Mol Ther (2016) 0.81
Getting personal with melanoma. Clin Cancer Res (2011) 0.79
Chimeric antibody receptors (CARs): driving T-cell specificity to enhance anti-tumor immunity. Front Biosci (Schol Ed) (2012) 0.79
Chimeric antigen receptor T cells: a novel therapy for solid tumors. J Hematol Oncol (2017) 0.78
CARs in chronic lymphocytic leukemia -- ready to drive. Curr Hematol Malig Rep (2013) 0.77
Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas. Cancer Immunol Res (2016) 0.76
Translational aspects in targeting the stromal tumour microenvironment: from bench to bedside. New Horiz Transl Med (2016) 0.75
CCR7(+) selected gene-modified T cells maintain a central memory phenotype and display enhanced persistence in peripheral blood in vivo. J Immunother Cancer (2017) 0.75
Cellular Immune Responses and Immune Escape Mechanisms in Breast Cancer: Determinants of Immunotherapy. Breast Care (Basel) (2016) 0.75
Driving better and safer HER2-specific CARs for cancer therapy. Oncotarget (2017) 0.75
Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74
Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 16.96
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med (2008) 11.49
Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer (2008) 9.82
Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia (2004) 3.59
A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther (2005) 3.18
Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci U S A (2004) 2.70
Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. J Clin Oncol (2006) 2.70
T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood (2006) 2.68
Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood (2007) 2.50
Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. Adv Exp Med Biol (2001) 2.42
Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol (1994) 2.10
Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood (2002) 1.89
Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood (2002) 1.83
Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer. J Exp Med (2004) 1.83
Targeting of G(D2)-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes. Int J Cancer (2001) 1.46
Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell. Clin Cancer Res (2007) 1.44
Localization of the gangliosides GD2 and GD3 in adhesion plaques and on the surface of human melanoma cells. Proc Natl Acad Sci U S A (1984) 1.39
Functional balance between T cell chimeric receptor density and tumor associated antigen density: CTL mediated cytolysis and lymphokine production. Gene Ther (2000) 1.24
Overexpression of the Notch ligand, Jagged-1, induces alloantigen-specific human regulatory T cells. Blood (2003) 1.23
Metastatic melanoma: chemotherapy. Semin Oncol (2002) 1.20
Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. J Clin Oncol (1994) 1.17
Phase I trial of the murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma. Cancer Res (1992) 1.12
Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Clin Cancer Res (2003) 1.12
Artificial T-cell receptors. Cytotherapy (2003) 1.07
Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors. Neoplasia (2001) 1.06
T cell retargeting with MHC class I-restricted antibodies: the CD28 costimulatory domain enhances antigen-specific cytotoxicity and cytokine production. J Immunol (2005) 1.01
Malignant transformation of human melanocytes: induction of a complete melanoma phenotype and genotype. Oncogene (1992) 1.00
Ganglioside vaccines with emphasis on GM2. Semin Oncol (1998) 0.91
Gangliosides of human melanoma. Cancer (1989) 0.90
Expression of the gangliosides GM3, GD3 and GD2 in tissue sections of normal skin, naevi, primary and metastatic melanoma. Int J Cancer (1988) 0.89
Ganglioside signatures of primary and nodal metastatic melanoma cell lines from the same patient. Melanoma Res (2008) 0.80
Heterogeneity in expression of human leukocyte antigens and melanoma-associated antigens in advanced melanoma. J Cell Physiol (2000) 0.80
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med (2008) 11.49
CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest (2011) 6.38
Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med (2011) 6.14
Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood (2009) 4.98
Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med (2006) 4.42
Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes. Blood (2004) 4.01
Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood (2007) 3.94
Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood (2011) 3.82
Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol (2013) 3.65
Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood (2010) 3.57
Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med (2004) 3.57
A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther (2005) 3.18
Interleukin-12: biological properties and clinical application. Clin Cancer Res (2007) 3.00
An inducible caspase 9 safety switch for T-cell therapy. Blood (2005) 2.93
CARs on track in the clinic. Mol Ther (2011) 2.86
T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood (2009) 2.79
T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood (2006) 2.68
Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood (2007) 2.50
Pharmacological activation of p53 triggers anticancer innate immune response through induction of ULBP2. Cell Cycle (2011) 2.43
Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell (2013) 2.35
Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant (2007) 2.33
Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood (2013) 2.13
Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood (2007) 2.11
Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase. J Invest Dermatol (2011) 2.09
NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J Clin Invest (2009) 2.08
Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. Blood (2010) 2.06
Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood (2002) 1.98
Midlife moments. Mol Ther (2011) 1.97
Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1/2 study. Lancet (2009) 1.96
Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood (2013) 1.95
Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood (2006) 1.93
Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood (2002) 1.89
Ex vivo fucosylation improves human cord blood engraftment in NOD-SCID IL-2Rγ(null) mice. Exp Hematol (2012) 1.85
Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex). J Immunother (2010) 1.81
Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev (2014) 1.81
Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood (2006) 1.75
Evidence for the presentation of major histocompatibility complex class I-restricted Epstein-Barr virus nuclear antigen 1 peptides to CD8+ T lymphocytes. J Exp Med (2004) 1.72
Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections. Mol Ther (2012) 1.72
Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy. J Virol (2007) 1.70
Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. Immunol Rev (2002) 1.66
Hypoxic adipocytes pattern early heterotopic bone formation. Am J Pathol (2007) 1.62
Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma. Cancer Res (2003) 1.60
Anti-CD45-mediated cytoreduction to facilitate allogeneic stem cell transplantation. Blood (2002) 1.59
Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort. J Transl Med (2014) 1.59
Regression of experimental medulloblastoma following transfer of HER2-specific T cells. Cancer Res (2007) 1.58
BRAF alterations are associated with complex mutational profiles in malignant melanoma. Oncogene (2004) 1.58
Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood (2004) 1.57
Conserved CTL epitopes on the adenovirus hexon protein expand subgroup cross-reactive and subgroup-specific CD8+ T cells. Blood (2004) 1.56
Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J Natl Cancer Inst (2002) 1.56
Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. Blood (2003) 1.55
Micro-RNA profiles in osteosarcoma as a predictive tool for ifosfamide response. Int J Cancer (2010) 1.54
Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications. Blood (2003) 1.54
The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells. Haematologica (2008) 1.54
Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood (2008) 1.52
Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J Immunother (2010) 1.50
Targeting heat shock proteins on cancer cells: selection, characterization, and cell-penetrating properties of a peptidic GRP78 ligand. Biochemistry (2006) 1.48
Primitive adult hematopoietic stem cells can function as osteoblast precursors. Proc Natl Acad Sci U S A (2003) 1.47
Fifteen years of gene therapy based on chimeric antigen receptors: "are we nearly there yet?". Hum Gene Ther (2009) 1.44
Coexpression of NRASQ61R and BRAFV600E in human melanoma cells activates senescence and increases susceptibility to cell-mediated cytotoxicity. Cancer Res (2006) 1.43
Target antigen expression on a professional antigen-presenting cell induces superior proliferative antitumor T-cell responses via chimeric T-cell receptors. J Immunother (2005) 1.41
Genetic modification of T lymphocytes for adoptive immunotherapy. Mol Ther (2004) 1.41
Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients. Cancer Res (2009) 1.41
Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood (2002) 1.40
Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). Blood (2009) 1.39
Introducing a new ASGCT forum for publication of methodology and clinical development in gene, cell, and oligonucleotide therapies. Mol Ther (2012) 1.39
CD45 monoclonal antibody-mediated cytolysis of human NK and T lymphoma cells. Haematologica (2006) 1.39